Adults 40 to 80, any sex, with Osteoarthritis, Hip. Patients with the condition only — healthy volunteers not accepted.
Results — posted to ClinicalTrials.gov
Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.
Number of Patients With Successful Study Drug AdministrationsPrimary· Day 1
Successful study drug administration, defined as Injector reporting complete study drug administration.
Group
Value
95% CI
FX006 32 mg
12
Adverse events — posted to ClinicalTrials.gov
Time frame: Adverse event data was collected from signing of informed consent to Last Visit..
Reporting threshold: 0%.
Adverse-event reports describe events observed during the trial — not all are caused by the drug.
This is a multi-center, single-arm, open-label study of FX006 in patients with hip OA. A maximum number of approximately 30 patients may be enrolled in this protocol. All enrolled patients will receive a single intra-articular (IA) injection of FX006.
Publications & conference data
2 peer-reviewed publications reference this trial (live from Europe PMC):
NCT03529942 — Study to Evaluate the Effect of FX006 on Synovial Inflammation in Patients With OA of the Knee
· Phase 3
· completed
NCT03382262 — Study to Compare Exposure of TA Following Administration of FX006 or TAcs in Patients With OA of the Shoulder or Hip
· Phase 2
· completed
NCT03378076 — Study to Compare Exposure of TA Following Administration of Either FX006 or TAcs in Patients With Bilateral Knee OA
· Phase 2
· completed
NCT03046446 — Study to Assess the Safety of Repeat Administration of FX006 Administered to Patients With Osteoarthritis of the Knee
· Phase 3
· completed
Other recruiting trials for Osteoarthritis, Hip
Currently open trials in the same condition.
NCT07386561 — Virtual Reality Therapy and Non-Sleep Deep Rest Relaxation After Joint Arthroplasty
· NA
· active not recruiting
NCT06578182 — The Effect of ColcHicine on the Incidence of Knee or Hip Replacements
· Phase 3
· recruiting
NCT06342843 — Direct Superior Approach Versus PosteroLateral Approach in Total Hip Arthroplasty (SPLAsH)
· NA
· recruiting
NCT06249958 — Transforming Rehabilitation: Personalised Care for a Better Quality of Life
· recruiting
NCT05700682 — Perfusion MRI-targeted Joint Embolization for Chronic Musculoskeletal Pain of the Shoulder, Hip and Knee
· recruiting
Other Pacira Pharmaceuticals, Inc trials
Trials by the same sponsor.
NCT06977568 — A Study to Evaluate an Intra-Articular Injection of ZILRETTA Versus Triamcinolone Acetonide, Immediate Release in Subjec
· Phase 2
· terminated
NCT05456490 — Phase 1, Dose Escalation Study to Evaluate of Safety, Pharmacokinetics and Pharmacodynamics of Liposomal Bupivacaine 13.
· Phase 1
· completed
NCT05157841 — Phase 3, Sciatic Nerve Block With EXPAREL for Subjects Undergoing Bunionectomy
· Phase 3
· completed
NCT05139030 — Phase 3 Adductor Canal Block With EXPAREL in Subjects Undergoing Primary Unilateral Total Knee Arthroplasty
· Phase 3
· completed
NCT05495334 — Innovations in Genicular Outcomes Registry
· recruiting
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Pacira Pharmaceuticals, Inc
Last refreshed: 24 January 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04065074.